Global Oncolytic Virotherapy Market Research 2024: Industry Size, Share, Trends, Opportunity & Forecasts, 2019-2029 - Focus on Personalized Medicine, Clinical Advancements Spurs Growth [Ya...
Novartis AG (NVS)
Last novartis ag earnings: 4/28 01:00 am
Check Earnings Report
US:NYSE Investor Relations:
novartis.com/investors
Company Research
Source: Yahoo! Finance
Size, Share, Trends, Opportunity & Forecast, 2019-2029F" report has been added to ResearchAndMarkets.com's offering. Global Oncolytic Virotherapy Market was valued at USD 21.22 Million in 2023 and is anticipated to project robust growth in the forecast period with a CAGR of 20.14% through 2029 The Global Oncolytic Virotherapy Market has witnessed significant growth and advancements in recent years, marking a transformative era in cancer treatment. Oncolytic virotherapy, a cutting-edge approach, utilizes viruses to selectively target and destroy cancer cells while sparing healthy ones. This innovative treatment method has gained momentum as a promising avenue in the field of oncology. The market's growth can be attributed to the increasing prevalence of various cancer types worldwide, driving the demand for novel and effective therapeutic interventions. One of the key factors propelling the Global Oncolytic Virotherapy Market is the extensive research and development activities f
Show less
Read more
Impact Snapshot
Event Time:
NVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVS alerts
High impacting Novartis AG news events
Weekly update
A roundup of the hottest topics
NVS
News
- NAVIGATE BIOPHARMA SERVICES, INC EARNS ACCREDITATION TO ISO 15189:2012 FROM CAPPR Newswire
- Novartis AG (NYSE: NVS) had its price target raised by analysts at BMO Capital Markets from $118.00 to $120.00. They now have a "market perform" rating on the stock.MarketBeat
- Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile [Yahoo! Finance]Yahoo! Finance
- Novartis to pay Monte Rosa $150 million upfront to develop a new class of drugs [Yahoo! Finance]Yahoo! Finance
- Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial [Yahoo! Finance]Yahoo! Finance
NVS
Earnings
- 10/29/24 - Beat
NVS
Sec Filings
- 10/29/24 - Form 6-K
- 10/29/24 - Form 6-K
- 9/18/24 - Form 6-K
- NVS's page on the SEC website